These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Aducanumab for Alzheimer's disease: Observations and opportunities. Pridmore W Australas Psychiatry; 2022 Oct; 30(5):598-600. PubMed ID: 36113474 [TBL] [Abstract][Full Text] [Related]
45. A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance? Luo JJ; Wallace W; Kusiak JW J Neurol Sci; 2022 Jul; 438():120294. PubMed ID: 35635864 [TBL] [Abstract][Full Text] [Related]
47. The Search for a Drug to End Alzheimer's. Campbell S IEEE Pulse; 2021; 12(2):2-7. PubMed ID: 33861693 [TBL] [Abstract][Full Text] [Related]
48. Aducanumab-Hope or Disappointment for Alzheimer's Disease. Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797 [TBL] [Abstract][Full Text] [Related]
49. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis? Silvestro S; Valeri A; Mazzon E Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126 [TBL] [Abstract][Full Text] [Related]
50. [Causal treatment of Alzheimer's disease: amyloid antibodies]. Pawlowski M; Warnecke T Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498 [TBL] [Abstract][Full Text] [Related]
51. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions? Burroughs AW; Krain LP AMA J Ethics; 2023 Oct; 25(10):E777-782. PubMed ID: 37801063 [TBL] [Abstract][Full Text] [Related]
52. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568 [TBL] [Abstract][Full Text] [Related]
53. Passive antiamyloid immunotherapy for Alzheimer's disease. Loureiro JC; Pais MV; Stella F; Radanovic M; Teixeira AL; Forlenza OV; de Souza LC Curr Opin Psychiatry; 2020 May; 33(3):284-291. PubMed ID: 32040044 [TBL] [Abstract][Full Text] [Related]
54. Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Marsool MDM; Prajjwal P; Reddy YB; Marsool ADM; Lam JR; Nandwana V Dis Mon; 2023 May; 69(5):101547. PubMed ID: 36931947 [TBL] [Abstract][Full Text] [Related]
55. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. Parums DV Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135 [TBL] [Abstract][Full Text] [Related]
56. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science]. Dal-Ré R Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583 [TBL] [Abstract][Full Text] [Related]
57. Aducanumab in Alzheimer's Disease: A Critical Update. Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K Curr Med Chem; 2024; 31(31):5004-5026. PubMed ID: 37497712 [TBL] [Abstract][Full Text] [Related]
58. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220 [TBL] [Abstract][Full Text] [Related]